|
|
| News Releases |
|
|
|
| Bridion® (sugammadex) has been chosen as the winner of the Nexxus 2008 West of Scotland Life Science Innovation Award |
| Reinvigorating West of Scotland Innovation |
| GLASGOW, Scotland, Nov. 13 -- With a plethora of industry awards being made right, left and centre these days it’s no wonder that the very thought of another of them might just have a soporific effect on you. Which is precisely why an award for a life science innovation which reinvigorates is worthy of attention! |
| read more > |
|
|
|
|
| Sugammadex Study First to Show Rapid Reversal of Profound Rocuronium-Induced Muscle Relaxation is Possible |
| Publication of Comparative Study Shows Sugammadex Provides Significantly Faster Reversal of Profound Rocuronium-Induced Muscle Relaxation than Neostigmine |
| KENILWORTH, N.J., Oct. 28 /PRNewswire-FirstCall/ -- Schering-Plough Corp., (NYSE: SGP) today announced that a study published in the November 2008 issue of the medical journal, Anesthesiology (Vol. 109, No. 5)(1) demonstrated that sugammadex produced a significantly more rapid recovery from profound rocuronium-induced muscle relaxation than the conventional reversal agent neostigmine. Importantly, this is the first comparative study to demonstrate that rapid reversal of profound rocuronium-induced muscle relaxation is possible. In the study, the median time to recovery was 2.7 minutes in the sugammadex group versus 49.0 minutes in the neostigmine group. |
| read more > |
|
|
|
|
| BRIDION® (sugammadex) Injection – first and only selective relaxant binding agent – approved in European Union |
| KENILWORTH, N.J., July 29 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that the European Commission (EC) has approved BRIDION(R) (sugammadex) injection, the first and only selective relaxant binding agent (SRBA) and the first major pharmaceutical advance in the field of anesthesia in two decades. BRIDION is indicated for routine reversal of the commonly used muscle relaxants rocuronium or vecuronium and for immediate reversal of rocuronium in adults, and for routine reversal following rocuronium in children and adolescents (2-17 years of age). Rocuronium and vecuronium are given as part of general anesthesia to relax a patient's muscles during surgery, and are marketed in Europe under the trade names ESMERON(R) and NORCURON(R), respectively. |
| read more > |
|
|
|
|
| Schering-Plough's Sugammadex provides fast reversal of effects of muscle relaxants used in general anesthesia |
| COPENHAGEN, Denmark, June 2 /PRNewswire-FirstCall/ -- Schering-Plough (NYSE: SGP) today announced that sugammadex, a novel experimental muscle relaxant reversal agent, reversed moderate (shallow) rocuronium- and vecuronium-induced muscle relaxation considerably faster than the current standard of care in reversal agents, according to data presented today at the annual meeting of the European Society of Anesthesiology (ESA), Euroanaesthesia 2008, in Copenhagen, Denmark. Due to the benefits that a faster reversal agent might offer, these results suggest that sugammadex could change the way muscle relaxation is practiced during anesthesia. |
| read more > |
|
|
|
|
| European Union's CHMP issues positive opinion on Sugammadex |
| KENILWORTH, N.J., June 2 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has recommended approval of sugammadex for routine reversal of the muscle relaxants rocuronium or vecuronium and for immediate reversal of rocuronium in adults, and for routine reversal following rocuronium in children and adolescents (2-17 years of age). Rocuronium and vecuronium are marketed in Europe under the trade names ESMERON(R) and NORCURON(R), respectively. |
| read more > |
|
|
